Maki Gouda

6PUBLICATIONS
10CO-AUTHORS
Toxicology (incl. clinical toxicology)Molecular medicinePharmacogenomicsMajor global burdens of diseaseCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 03, 2024
Analysis of Antipsychotic Dosage in Patients With Tardive Dyskinesia: A Case-Control Study Using the Claims Database of the Corporate Health Insurance Association.

Maki Gouda, Michikazu Abe, Yumi Watanabe

|Feb 27, 2024
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.

Hiroaki Iijima, Maki Gouda, Hideaki Hida

|Jul 20, 2022
Effect of sodium-glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using the JMDC Claims Database.

Maki Gouda, Kenji Arakawa, Masaya Inagaki

|May 14, 2021
Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database.

Koutaro Yokote, Ryo Suzuki, Maki Gouda

|Apr 15, 2019
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.

Antonio Ceriello, Valeria De Nigris, Hiroaki Iijima

|Feb 09, 2017
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.

Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo

Pageof 1

Frequent Collaborators

3 joint publications

Hiroaki Iijima

1 joint publications

Antonio Ceriello

1 joint publications

Valeria De Nigris

1 joint publications

Koutaro Yokote